CORE LAB REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
Rhea-AI Summary
Core Laboratories (NYSE: CLB) reported Q4 2025 revenue of $138.3M, up 3% sequentially and 7% year-over-year, with GAAP operating income of $15.8M and GAAP EPS of $0.15. Full year 2025 revenue was $526.5M, GAAP operating income $56.5M, and GAAP EPS $0.68. The company generated $26.0M free cash flow for 2025, reduced net debt by $18.7M (over 17%), repurchased ~1.2M shares for $15.5M, and declared a quarterly cash dividend of $0.01 per share.
Positive
- Q4 revenue of $138.3M, up 7% YoY
- Full year free cash flow of $26.0M
- Net debt reduced by $18.7M (over 17%) in 2025
- Share repurchases of ~1.2M shares for $15.5M in 2025
Negative
- Full year operating income, ex-items, down 10%
- Full year EPS, ex-items, down 14%
- Tariff-driven raw material costs and a provision for a potentially uncollectible receivable pressured margins
Key Figures
Market Reality Check
Peers on Argus
CLB was modestly higher (+0.26%) while key peers were mixed: PUMP -5.57%, ACDC -2.14%, NPKI -4.57%, NESR -1.73%, RES +3.47%. This points to a company-specific reaction rather than a broad sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 22 | Q3 2025 earnings | Positive | +6.1% | Q3 2025 revenue and EPS met guidance with solid free cash flow. |
| Oct 22 | Q3 2025 earnings | Positive | +6.1% | Q3 2025 results plus Solintec acquisition and ongoing buybacks. |
| Jul 23 | Q2 2025 earnings | Positive | +5.9% | Q2 2025 revenue growth, higher FCF, and net debt reduction. |
| Apr 23 | Q1 2025 earnings | Negative | -3.8% | Q1 2025 revenue decline and low GAAP EPS amid macro headwinds. |
| Jan 29 | Q4 2024 & FY 2024 | Negative | -4.3% | Q4 2024 soft sequential revenue but strong FCF and deleveraging. |
Recent earnings releases have typically seen the stock move several percent, with most reactions aligning directionally with the tone of the results.
Over the last year, Core Lab’s earnings updates have shown steady revenue in the $123M–$135M quarterly range, with margins and EPS influenced by international activity, sanctions, and tariffs. Q1 2025 results were softer, while Q2 and Q3 2025 showed improving revenue, free cash flow, and net debt reduction. The Q4 2024 release highlighted strong FCF and deleveraging. Today’s Q4 2025 and full-year 2025 report continues themes of modest revenue growth, ongoing share repurchases, and measured debt reduction.
Historical Comparison
Recent earnings releases for CLB have typically moved the stock about 2% on average, with reactions generally tracking the tone of each report.
Earnings releases from Q4 2024 through Q3 2025 show modest revenue growth, improving leverage, and consistent buybacks, leading into the Q4 2025 and full-year 2025 update.
Market Pulse Summary
This announcement details Q4 2025 revenue of $138.3M and full-year 2025 revenue of $526.5M, alongside full-year EPS ex-items of $0.75. Core Lab continued to generate free cash flow, reducing net debt to $90.2M and leverage to 1.09, while maintaining a $0.01 quarterly dividend and repurchasing shares. Investors may watch how 2026 guidance, tariff and weather headwinds, and U.S. land activity trends affect margins, cash generation, and further deleveraging.
Key Terms
free cash flow financial
non-GAAP financial
return on invested capital financial
term loan financial
Schedule 13G regulatory
AI-generated analysis. Not financial advice.
- FOURTH QUARTER REVENUE OF
MILLION, UP$138.3 3% SEQUENTIALLY AND UP7% YEAR-OVER-YEAR - FOURTH QUARTER OPERATING INCOME OF
; EX-ITEMS,$15.8 MILLION , DOWN$15.7 MILLION 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR - FOURTH QUARTER OPERATING MARGINS, EX-ITEMS, OF OVER
11% , DOWN 100 BASIS POINTS SEQUENTIALLY AND 80 BASIS POINTS YEAR-OVER-YEAR - FOURTH QUARTER GAAP EPS OF
; EX-ITEMS,$0.15 , DOWN$0.21 4% SEQUENTIALLY AND YEAR-OVER-YEAR - FOURTH QUARTER FREE CASH FLOW OF
$5.1 MILLION - NET DEBT REDUCED BY
; LEVERAGE RATIO IMPROVED TO 1.09$1.2 MILLION - COMPANY REPURCHASED 363,207 SHARES OF COMMON STOCK, FOR
AGGREGATE PURCHASE PRICE$5.7 MILLION - COMPANY ANNOUNCES Q1 2026 QUARTERLY DIVIDEND
- FULL YEAR REVENUE OF
, UP SLIGHTLY$526.5 MILLION - FULL YEAR OPERATING INCOME OF
; EX-ITEMS,$56.5 MILLION , DOWN$58.7 MILLION 10% - FULL YEAR GAAP EPS OF
UP$0.68 3% ; EX-ITEMS, EPS OF , DOWN$0.75 14% - FULL YEAR FREE CASH FLOW OF
$26.0 MILLION - FULL YEAR NET DEBT REDUCED BY
OR OVER$18.7 MILLION 17% - FULL YEAR COMPANY REPURCHASED APPROXIMATELY 1.2 MILLION SHARES OF COMMON STOCK,
AGGREGATE PURCHASE PRICE$15.5 MILLION
Core's CEO, Larry Bruno, stated, "Core Lab's fourth quarter results were highlighted by sequential and year-over-year revenue growth that exceeded our provided guidance range for the quarter. This was driven by strong international demand for the Company's proprietary technologies, which helped offset a seasonally soft
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately
In the fourth quarter, Core Lab successfully completed phase one of a comprehensive study for an NOC in the
Also during the fourth quarter, Core Lab experienced an increase in regional study sales focused on
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
In the fourth quarter of 2025, Core Lab successfully completed an offshore plug and abandonment project on a deepwater Gulf of America well using its proprietary PAC™ technology. Core's PAC™ system was selected to enable annular access for permanent cement barrier placement where conventional section milling presented operational and scheduling risks. The operation was completed in approximately four days, exceeding client expectations. Based on typical offshore milling durations and current day rates, the use of Core Lab's PAC™ system is estimated to have reduced execution time by up to five days and lowered well cost by approximately half-million dollars. Core's PAC™ system is a widely proven and accepted technology, and adoption of this technology is expanding beyond its traditional geographic markets.
Also, during the fourth quarter, a major deepwater operator engaged Core Lab to deploy its innovative, thru-pipe top-of-cement tracing technology using Core's proprietary SpectraStim® tracers for their riserless completions. Riserless cementing is often employed offshore as a cost-effective technique for setting conductor and surface casings where the seabed is unstable or where shallow gas hazards exist. Due to the instability of these zones, lightweight, low-density foamed cement is often utilized for setting these shallow casing strings. It is very important to ensure zonal coverage with the foamed cement. However, because foamed cement has a low acoustic impedance, traditional cement bond logs are notoriously ineffective in evaluating coverage. Core's SpectraStim® tracing successfully confirmed zonal coverage by the foamed cement and satisfied the offshore regulatory requirements in a cost-effective manner.
Liquidity, Free Cash Flow, Share Repurchases, and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the fourth quarter of 2025, cash from operations was
As mentioned in the Company's prior earnings releases, in February 2024, fire damaged a building on the campus of Core Lab's Advanced Technology Center in
On October 1, 2025, Core Lab completed the acquisition of Brazilian-based Solintec Consultoria E Servicos De Geologia Ltda. ("Solintec"), for an initial cash payment of approximately
In the fourth quarter of 2025, Core Lab repurchased 363,207 shares at an aggregate purchase price of approximately
As of December 31, 2025, Core's net debt (defined as long-term debt less cash and cash equivalents) was
On October 22, 2025, Core's Board of Directors ("Board") announced a quarterly cash dividend of
On February 4, 2026, the Board approved a cash dividend of
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield services companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, the Company's ROIC for the fourth quarter of 2025 at
Industry and Core Lab Outlook and Guidance
The IEA, EIA, and OPEC+ forecast global crude oil demand growth of approximately 0.9–1.4 million barrels per day in 2026, a slight increase from their previous forecasts. As discussed in Core Lab's third quarter release, the IEA published a report in September 2025 which noted accelerating natural decline rates in existing producing fields pose a significant long-term supply risk. This analysis underpins the need for sustained investment in oil and gas developments to maintain energy security and market stability. In the
In the near term, tariff pressures and OPEC+ production policy decisions continue to contribute to market volatility and softer commodity prices. Despite these headwinds, longer-term crude oil demand fundamentals remain strong. Core Lab maintains a constructive multi-year outlook and continues to see steady activity across committed long-cycle projects, including deepwater developments in the South Atlantic Margin, North and
Geopolitical conflicts and associated sanctions, evolving trade and tariff dynamics, and commodity price volatility continue to create uncertainty in demand for Core Lab's products and services. Core also expects seasonal patterns to result in the typical sequential decline in activity during the first quarter of 2026. Severe weather events in
For the first half of 2026, Core Lab anticipates
To date, tariffs have not had a significant impact to Core Lab's Reservoir Description segment. However, for Production Enhancement operations, certain imported raw materials are subject to tariffs. While tariffs are increasing supply costs and affecting margins, the Company continues to take steps to mitigate their impact.
Consequently, Reservoir Description's first quarter 2026 revenue is projected to range from
Core's first quarter 2026 revenue is projected to range from
The Company's first quarter 2026 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. The first quarter guidance also reflects a higher interest rate related to a term loan drawn upon on January 12, 2026, in the amount of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's fourth quarter and full year 2025 earnings announcement. The call will begin at 7:30 a.m. CST / 8:30 a.m. EST on Thursday, February 5, 2026. To log on to the listen-only webcast, visit www.corelab.com/investors 15 minutes before the start of the call. For those not available to listen to the live webcast, a replay and transcript will be available on the Company's website shortly after the call. Analysts may contact investor.relations@corelab.com for conference call dial-in information.
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements Core Lab makes, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the impact of tariffs, trade policies and sanctions, international markets, international political climates, including the
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com.
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||||||||||||
Quarter Ended | % Variance | |||||||||||||||
December 31, | September 30, | December 31, | vs. Q3-2025 | vs. Q4-2024 | ||||||||||||
REVENUE | $ | 138,255 | $ | 134,521 | $ | 129,237 | 2.8 % | 7.0 % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 109,516 | 104,901 | 106,199 | 4.4 % | 3.1 % | |||||||||||
General and administrative | 10,631 | 10,688 | 9,080 | (0.5) % | 17.1 % | |||||||||||
Depreciation and amortization | 3,668 | 3,594 | 3,664 | 2.1 % | 0.1 % | |||||||||||
Other (income) expense, net | (1,392) | (5,590) | (3,880) | NM | NM | |||||||||||
Total operating expenses | 122,423 | 113,593 | 115,063 | 7.8 % | 6.4 % | |||||||||||
OPERATING INCOME | 15,832 | 20,928 | 14,174 | (24.4) % | 11.7 % | |||||||||||
Interest expense | 2,609 | 2,650 | 2,629 | (1.5) % | (0.8) % | |||||||||||
Income before income taxes | 13,223 | 18,278 | 11,545 | (27.7) % | 14.5 % | |||||||||||
Income tax expense | 5,960 | 3,754 | 4,076 | 58.8 % | 46.2 % | |||||||||||
Net income | 7,263 | 14,524 | 7,469 | (50.0) % | (2.8) % | |||||||||||
Net income attributable to non- | 181 | 285 | 66 | NM | NM | |||||||||||
Net income attributable to Core | $ | 7,082 | $ | 14,239 | $ | 7,403 | (50.3) % | (4.3) % | ||||||||
Diluted earnings per share | $ | 0.16 | $ | 0.31 | $ | 0.16 | (48.4) % | — % | ||||||||
Diluted earnings per share | $ | 0.15 | $ | 0.30 | $ | 0.15 | (50.0) % | — % | ||||||||
Diluted weighted average common | 46,697 | 47,078 | 47,773 | (0.8) % | (2.3) % | |||||||||||
Effective tax rate | 45 | % | 21 | % | 35 | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 92,282 | $ | 88,224 | $ | 86,793 | 4.6 % | 6.3 % | ||||||||
Production Enhancement | 45,973 | 46,297 | 42,444 | (0.7) % | 8.3 % | |||||||||||
Consolidated | $ | 138,255 | $ | 134,521 | $ | 129,237 | 2.8 % | 7.0 % | ||||||||
Operating income: | ||||||||||||||||
Reservoir Description | $ | 12,823 | $ | 16,574 | $ | 16,643 | (22.6) % | (23.0) % | ||||||||
Production Enhancement | 3,025 | 4,379 | (2,597) | (30.9) % | 216.5 % | |||||||||||
Corporate and Other | (16) | (25) | 128 | NM | NM | |||||||||||
Consolidated | $ | 15,832 | $ | 20,928 | $ | 14,174 | (24.4) % | 11.7 % | ||||||||
"NM" means not meaningful | ||||||||||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||||||
Year Ended December 31, | % Variance | |||||||||
2025 | 2024 | |||||||||
REVENUE | $ | 526,520 | $ | 523,848 | 0.5 % | |||||
OPERATING EXPENSES: | ||||||||||
Costs of services and product sales | 417,587 | 420,522 | (0.7) % | |||||||
General and administrative expense | 45,430 | 39,770 | 14.2 % | |||||||
Depreciation and amortization | 14,649 | 14,953 | (2.0) % | |||||||
Other (income) expense, net | (7,614) | (9,953) | NM | |||||||
Total operating expenses | 470,052 | 465,292 | 1.0 % | |||||||
OPERATING INCOME | 56,468 | 58,556 | (3.6) % | |||||||
Interest expense | 10,572 | 12,369 | (14.5) % | |||||||
Income before income taxes | 45,896 | 46,187 | (0.6) % | |||||||
Income tax expense | 13,371 | 14,034 | (4.7) % | |||||||
Net income | 32,525 | 32,153 | 1.2 % | |||||||
Net income attributable to non-controlling interest | 722 | 753 | NM | |||||||
Net income attributable to Core Laboratories Inc. | $ | 31,803 | $ | 31,400 | 1.3 % | |||||
Diluted earnings per share | $ | 0.69 | $ | 0.67 | 3.0 % | |||||
Diluted earnings per share attributable to Core Laboratories Inc. | $ | 0.68 | $ | 0.66 | 3.0 % | |||||
Diluted weighted average common shares outstanding | 47,028 | 47,685 | (1.4) % | |||||||
Effective tax rate | 29 | % | 30 | % | NM | |||||
SEGMENT INFORMATION: | ||||||||||
Revenue: | ||||||||||
Reservoir Description | $ | 347,683 | $ | 346,146 | 0.4 % | |||||
Production Enhancement | 178,837 | 177,702 | 0.6 % | |||||||
Total | $ | 526,520 | $ | 523,848 | 0.5 % | |||||
Operating income: | ||||||||||
Reservoir Description | $ | 43,939 | $ | 51,466 | (14.6) % | |||||
Production Enhancement | 12,055 | 6,612 | 82.3 % | |||||||
Corporate and Other | 474 | 478 | (0.8) % | |||||||
Total | $ | 56,468 | $ | 58,556 | (3.6) % | |||||
"NM" means not meaningful | ||||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||||||||||
% Variance | ||||||||||||||||
ASSETS: | December 31, | September 30, | December 31, | vs. Q3-2024 | vs. Q4-2024 | |||||||||||
Cash and cash equivalents | $ | 22,847 | $ | 25,629 | $ | 19,157 | (10.9) % | 19.3 % | ||||||||
Accounts receivable, net | 113,528 | 110,258 | 111,761 | 3.0 % | 1.6 % | |||||||||||
Inventories | 54,496 | 58,241 | 59,402 | (6.4) % | (8.3) % | |||||||||||
Other current assets | 31,495 | 32,786 | 36,286 | (3.9) % | (13.2) % | |||||||||||
Total current assets | 222,366 | 226,914 | 226,606 | (2.0) % | (1.9) % | |||||||||||
Property, plant and equipment, net | 99,447 | 98,031 | 97,063 | 1.4 % | 2.5 % | |||||||||||
Right of use assets | 54,346 | 53,980 | 56,488 | 0.7 % | (3.8) % | |||||||||||
Intangibles, goodwill and other long- | 220,793 | 212,435 | 210,249 | 3.9 % | 5.0 % | |||||||||||
Total assets | $ | 596,952 | $ | 591,360 | $ | 590,406 | 0.9 % | 1.1 % | ||||||||
LIABILITIES AND EQUITY: | ||||||||||||||||
Accounts payable | $ | 37,275 | $ | 36,945 | $ | 34,549 | 0.9 % | 7.9 % | ||||||||
Short-term operating lease liabilities | 11,456 | 11,474 | 10,690 | (0.2) % | 7.2 % | |||||||||||
Other current liabilities | 58,440 | 47,324 | 52,347 | 23.5 % | 11.6 % | |||||||||||
Total current liabilities | 107,171 | 95,743 | 97,586 | 11.9 % | 9.8 % | |||||||||||
Long-term debt, net | 110,255 | 114,103 | 126,111 | (3.4) % | (12.6) % | |||||||||||
Long-term operating lease liabilities | 42,309 | 41,525 | 43,343 | 1.9 % | (2.4) % | |||||||||||
Other long-term liabilities | 57,457 | 62,601 | 65,630 | (8.2) % | (12.5) % | |||||||||||
Total equity | 279,760 | 277,388 | 257,736 | 0.9 % | 8.5 % | |||||||||||
Total liabilities and equity | $ | 596,952 | $ | 591,360 | $ | 590,406 | 0.9 % | 1.1 % | ||||||||
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | |||||||
Year Ended December 31, | |||||||
2025 | 2024 | ||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net income | $ | 32,525 | $ | 32,153 | |||
Adjustments to reconcile net income to net cash provided by operating | |||||||
Stock-based compensation | 7,137 | 3,755 | |||||
Depreciation and amortization | 14,649 | 14,953 | |||||
Deferred income taxes | (4,739) | 674 | |||||
Insurance recovery on property, plant and equipment | (6,830) | (4,398) | |||||
Accounts receivable | (4,953) | (3,612) | |||||
Inventories | 2,644 | 9,367 | |||||
Accounts payable | 477 | 519 | |||||
Other adjustments to net income | (3,734) | 2,977 | |||||
Net cash provided by operating activities | 37,176 | 56,388 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Capital expenditures - operations | (11,209) | (11,888) | |||||
Capital expenditures - rebuilding of | (3,380) | (1,140) | |||||
Net proceeds from insurance recovery - | 9,951 | 2,102 | |||||
Acquisitions, net of cash acquired | (1,237) | — | |||||
Net proceeds from life insurance policies | 778 | 2,776 | |||||
Other investing activities | 2,866 | 1,756 | |||||
Net cash used in investing activities | (2,231) | (6,394) | |||||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Repayment of long-term debt | (63,000) | (82,000) | |||||
Proceeds from long-term debt | 48,000 | 44,000 | |||||
Equity related transaction costs | — | (756) | |||||
Debt issuance costs | (1,706) | (19) | |||||
Dividends paid | (1,869) | (1,876) | |||||
Repurchase of common stock | (12,426) | (5,306) | |||||
Other financing activities | (254) | — | |||||
Net cash used in financing activities | (31,255) | (45,957) | |||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 3,690 | 4,037 | |||||
CASH AND CASH EQUIVALENTS, beginning of year | 19,157 | 15,120 | |||||
CASH AND CASH EQUIVALENTS, end of year | $ | 22,847 | $ | 19,157 | |||
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income, Net Income and Diluted Earnings Per Share Attributable to Core Laboratories Inc. (In thousands, except per share data) (Unaudited) | |||||||||||
Operating Income | |||||||||||
Quarter Ended | |||||||||||
December 31, 2025 | September 30, 2025 | December 31, | |||||||||
GAAP reported | $ | 15,832 | $ | 20,928 | $ | 14,174 | |||||
Stock compensation (1) | — | — | (771) | ||||||||
Inventory and asset write-downs and severance (2) | — | 601 | 4,115 | ||||||||
Insurance recovery on property, plant and equipment (3) | — | (5,252) | (2,572) | ||||||||
Foreign exchange losses (gains) | (95) | 354 | 761 | ||||||||
Excluding specific items | $ | 15,737 | $ | 16,631 | $ | 15,707 | |||||
Net Income Attributable to Core Laboratories Inc. | |||||||||||
Quarter Ended | |||||||||||
December 31, 2025 | September 30, 2025 | December 31, 2024 | |||||||||
GAAP reported | $ | 7,082 | $ | 14,239 | $ | 7,403 | |||||
Stock compensation (1) | — | — | (617) | ||||||||
Inventory and asset write-downs and severance (2) | — | 451 | 3,292 | ||||||||
Insurance recovery on property, plant and equipment (3) | — | (3,939) | (2,058) | ||||||||
Foreign exchange losses (gains) | (72) | 265 | 610 | ||||||||
Effect of higher (lower) tax rate (4) | 2,654 | (815) | 1,766 | ||||||||
Excluding specific items | $ | 9,664 | $ | 10,201 | $ | 10,396 | |||||
Diluted Earnings Per Share Attributable to Core Laboratories Inc. | |||||||||||||||
Quarter Ended | Year ended | ||||||||||||||
December 31, | September 30, | December 31, | December 31, | ||||||||||||
GAAP reported | $ | 0.15 | $ | 0.30 | $ | 0.15 | $ | 0.68 | |||||||
Stock compensation (1) | — | — | (0.01) | 0.05 | |||||||||||
Inventory and asset write-downs, lease | — | 0.01 | 0.07 | 0.08 | |||||||||||
Insurance recovery on property, plant and | — | (0.08) | (0.04) | (0.11) | |||||||||||
Foreign exchange losses (gains) | — | 0.01 | 0.01 | 0.01 | |||||||||||
Effect of higher (lower) tax rate (4) | 0.06 | (0.02) | 0.04 | 0.04 | |||||||||||
Excluding specific items | $ | 0.21 | $ | 0.22 | $ | 0.22 | $ | 0.75 | |||||||
(1) The three months ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance conditions for certain executives' share awards and the acceleration of stock compensation expense associated with employees reaching eligible retirement age. | |||||||||||||||
(2) Includes the write-down of inventory, leasehold improvements, and/or other assets and exit costs associated with consolidation of certain facilities. | |||||||||||||||
(3) Includes recovery of insurance proceeds associated with the fire at the | |||||||||||||||
(4) The three months ended December 31, 2024 includes the effect to reflect tax expense at a normalized rate of |
Segment Information (In thousands) (Unaudited) | |||||||||||
Operating Income | |||||||||||
Quarter Ended December 31, 2025 | |||||||||||
Reservoir | Production | Corporate and | |||||||||
GAAP reported | $ | 12,823 | $ | 3,025 | $ | (16) | |||||
Foreign exchange losses (gains) | (111) | 3 | 13 | ||||||||
Excluding specific items | $ | 12,712 | $ | 3,028 | $ | (3) | |||||
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is defined as net cash provided by operating activities (which is the most directly comparable GAAP measure) less cash paid for capital expenditures - operations. Management believes that free cash flow provides useful information to investors regarding the cash available in the period in excess of Core's needs to fund its capital expenditures and operating activities. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash does not represent residual cash available for distribution because Core may have other non-discretionary expenditures that are not deducted from the measure. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow (In thousands) (Unaudited) | |||||||
Quarter Ended | Year Ended | ||||||
December 31, 2025 | December 31, 2025 | ||||||
Net cash provided by operating activities | $ | 8,091 | $ | 37,176 | |||
Capital expenditures - operations | (2,944) | (11,209) | |||||
Free cash flow | $ | 5,147 | $ | 25,967 | |||
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-fourth-quarter-and-full-year-2025-results-302679533.html
SOURCE Core Laboratories Inc
